Results 261 to 270 of about 101,617 (297)

DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control

Archives of Pharmacal Research, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are an emerging class of antidiabetic drugs that constitutes approximately fifty percent of the market share of the oral hypoglycemic drugs. Its mechanism of action for lowering blood glucose is essentially via inhibition of the rapid degradation of incretin hormones, such as glucagon-like peptide ...
openaire   +2 more sources

Inappropriate Use of DPP-4 Inhibitors

2014
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents for the treatment of type 2 diabetes. They have shown reduction of blood glucose, but potential impact on cardiovascular outcomes and long-term safety remain inconclusive. For that reasons DPP-4[for full text, please go to the a.m. URL]
Reichel, A, Blank, S, Tamminga, M, Schoch, GG, Steimle, T   +4 more
openaire   +1 more source

How safe are DPP‐4 inhibitors?

Practical Diabetes, 2013
AbstractAbstract.
Laura McCreight, Miles Fisher
openaire   +1 more source

Cardiovascular safety and DPP‐4 inhibitors

Practical Diabetes, 2013
Abstract Following the rosiglitazone controversy there is a requirement from the licensing agencies that new antidiabetic drugs must be shown not to increase cardiovascular risk during phase 3 development. This includes studying patients with high cardiovascular risk, who were previously excluded from phase 3 studies.
David M Carty, Russell Drummond, Miles Fisher   +2 more
openaire   +1 more source

[DPP-4 inhibitors in nephropatics].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
The use of glucose-lowering drugs in advanced stage diabetic nephropathic patients should be done very carefully. Some drugs are contraindicated or not recommended. The same insulin needs a dose reduction to avoid dangerous hypoglycemia. For some years the use of inhibitors of the DDP-4 has been approved in T2DM patients with CKD III and IV stage ...
Annamaria, Bruzzese, Maria, Pasquale, Carmela, Aloisi, Giuseppe, Costantino, Michele, Buemi   +4 more
openaire   +1 more source

[Once-weekly DPP-4 inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2016
Trelagliptin is the first once-weekly dipeptidyl peptidase-4(DPP-4) inhibitor in the world. Trelagliptin inhibits DPP-4 activity with lower drug concentration compared with other once- (or twice-) daily DPP-4 inhibitors in in vitro study. More than 70 % of DPP-4 activity is inhibited even 1 week after administration of trelagliptin administration in ...
Norio, Harada, Nobuya, Inagaki
openaire   +1 more source

DPP-4 Inhibitors

2017
T. Biftu, R. SinhaRoy
openaire   +1 more source

Synthesis of a DPP-4 Inhibitor

Synfacts, 2020
openaire   +1 more source

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control

Clinical Medicine Insights: Endocrinology and Diabetes, 2021
Seon Mee Kang, Jeong Hyun Park
exaly  

Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids

Pharmaceuticals, 2021
Ahmed A E Mourad, Ahmed E Khodir, Sameh Saber   +2 more
exaly